Breakthrough MDD Drug.
Helus Pharma's FDA Breakthrough Depression Drug HLP003 Nears Phase 3 Completion.
Helus Pharma (NASDAQ: HELP), the company formerly known as Cybin Inc., announced that its APPROACH Phase 3 trial has surpassed 86% enrollment, keeping the program on track for a topline data readout in Q4 2026, according to GlobeNewswire. The drug, HLP003, carries FDA Breakthrough Therapy Designation — a status given to treatments that show early signs of major improvement over existing options.
Shares of HELP jumped as much as 28.9% on the news, reflecting investor relief that timelines are holding despite a turbulent few months of leadership changes at the top of the company, Financial Post reported.
What HLP003 Is and Why the FDA Is Watching
HLP003 is a deuterated psilocybin analog — a lab-modified version of the psychedelic compound psilocybin. Deuteration swaps out hydrogen atoms for a heavier version, making the molecule more stable. The result is a drug with a faster onset of under 15 minutes and a shorter duration of 4–6 hours, compared to up to 8 hours for traditional psilocybin, according to Vancouver Sun.
Helus targets the 21 million U.S. adults living with MDD who remain symptomatic despite taking standard antidepressants like SSRIs. Most rival psychedelic trials, such as those by Compass Pathways, have focused on treatment-resistant depression — a much smaller population. Helus is betting on a broader "adjunctive" approach, meaning HLP003 would be added on top of existing medications rather than replace them, Calgary Herald reported.
Phase 2 Numbers That Drove the Breakthrough Designation
The FDA's Breakthrough Therapy label was granted in March 2024, based on Phase 2 data that turned heads. At the 12-month mark, 100% of patients showed a clinical response and 71% achieved remission, Canada Newswire reported. The average score on the Montgomery-Asberg Depression Rating Scale — a standard measure of depression severity — dropped by 23 points.
CMO Amir Inamdar said the adjunctive strategy is deliberate. "An adjunctive MDD indication could position HLP003 earlier in the patient treatment journey — before they become resistant," he said, according to Owen Sound Sun Times. The APPROACH trial is part of a broader three-study program called PARADIGM, which also includes the EMBRACE and EXTEND studies for longer-term durability data.
Leadership Shake-Up Clouds an Otherwise Steady Trial
The clinical progress stands in contrast to boardroom instability. In February 2026, Helus hired Big Pharma veteran Michael Cola as CEO. Just 70 days later, in April 2026, the board pushed him out. Co-founder Eric So stepped back in as Interim CEO, according to Vancouver Sun. Some analysts called the move a red flag at a critical moment before Phase 3 results arrive.
On June 24, the same day Helus announced the 86% enrollment milestone, the company also priced a $50 million stock offering at $4.85 per share — a discount to its then-market price of roughly $5.66, Financial Post noted. So said the milestone "underscores the execution of our clinical program and brings us closer to the anticipated topline data readout in the fourth quarter of 2026."
Key Risks Before the Q4 Data Readout
Not everyone is convinced. A June 2026 meta-analysis published in JAMA Psychiatry found that when "functional unblinding" is factored in — meaning patients likely know they got the active drug because of the psychedelic experience — psychedelics may only match, not beat, traditional antidepressants. This could push the FDA to demand tougher control groups or higher efficacy thresholds, Montreal Gazette reported.
Investors also face dilution risk. The $50 million raise extends the company's cash runway into 2027, but the company has yet to generate revenue. Helus projects $174 million in annual revenue by 2029, assuming a successful launch the year prior, according to The Whig. That projection hinges entirely on Q4 2026 data coming in strong.
Sentiment
NeutralPublishers
17
Articles
17
Reach
17
